Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Warnock

Showing results (151-160 of 209) with videos related to

Pageof 21
Sort By:
Journal of Medical Genetics|March 13, 2020
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroupDominique P Germain, João Paulo Oliveira, Daniel G Bichet, et al.
Plos One|June 18, 2015
Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement TherapySachie Nakano, Takahiro Tsukimura, Tadayasu Togawa, et al.
Pediatric Nephrology (Berlin, Germany)|August 1, 2007
Improving outcomes from acute kidney injury: report of an initiativeArvind Bagga, Aysin Bakkaloglu, Prasad Devarajan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2005
Delay in time to receipt of thrombolytic medication among Medicare patients with kidney diseaseBritt B Newsome, David G Warnock, Catarina I Kiefe, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 13, 2008
Racial differences in the competing risks of mortality and ESRD after acute myocardial infarctionBritt B Newsome, William M McClellan, Jeroan J Allison, et al.
Annals of Internal Medicine|December 21, 2006
Agalsidase-beta therapy for advanced Fabry disease: a randomized trialMaryam Banikazemi, Jan Bultas, Stephen Waldek, et al.
Cardiorenal Medicine|June 7, 2019
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney DiseaseDana V Rizk, Arnold L Silva, Pablo E Pergola, et al.
Orphanet Journal of Rare Diseases|December 21, 2021
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithmJohn L Jefferies, Alison K Spencer, Heather A Lau, et al.
American Journal of Nephrology|February 9, 2013
Healthy behaviors, risk factor control and awareness of chronic kidney diseaseDelphine S Tuot, Laura C Plantinga, Suzanne E Judd, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 23, 2014
Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) StudyPaul Muntner, Orlando M Gutiérrez, Hong Zhao, et al.
Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:
Pageof 21
Journal of Medical Genetics|March 13, 2020
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroupDominique P Germain, João Paulo Oliveira, Daniel G Bichet, et al.
Plos One|June 18, 2015
Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement TherapySachie Nakano, Takahiro Tsukimura, Tadayasu Togawa, et al.
Pediatric Nephrology (Berlin, Germany)|August 1, 2007
Improving outcomes from acute kidney injury: report of an initiativeArvind Bagga, Aysin Bakkaloglu, Prasad Devarajan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2005
Delay in time to receipt of thrombolytic medication among Medicare patients with kidney diseaseBritt B Newsome, David G Warnock, Catarina I Kiefe, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 13, 2008
Racial differences in the competing risks of mortality and ESRD after acute myocardial infarctionBritt B Newsome, William M McClellan, Jeroan J Allison, et al.
Annals of Internal Medicine|December 21, 2006
Agalsidase-beta therapy for advanced Fabry disease: a randomized trialMaryam Banikazemi, Jan Bultas, Stephen Waldek, et al.
Cardiorenal Medicine|June 7, 2019
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney DiseaseDana V Rizk, Arnold L Silva, Pablo E Pergola, et al.
Orphanet Journal of Rare Diseases|December 21, 2021
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithmJohn L Jefferies, Alison K Spencer, Heather A Lau, et al.
American Journal of Nephrology|February 9, 2013
Healthy behaviors, risk factor control and awareness of chronic kidney diseaseDelphine S Tuot, Laura C Plantinga, Suzanne E Judd, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 23, 2014
Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) StudyPaul Muntner, Orlando M Gutiérrez, Hong Zhao, et al.
Pageof 21